Bide Pharmaceutical's net profit in 2024 increased by 7.17% year-on-year, with the Overseas market becoming the growth engine.

In 2024, Bid achieved an annual revenue of 1.102 billion yuan, a year-on-year increase of 0.93%; the net income attributable to the parent company's shareholders was 0.117 billion yuan, a year-on-year increase of 7.17%; the company stated it will continue to optimize the product structure, deepen its global layout, and increase R&D investment to respond to changes in the industry technology.

cls.cn00:29 ET

Shanghai Medicilon Inc.'s revenue in 2024 declined by over 20%, with losses further expanding.

① Affected by multiple factors such as the slowdown in investment and financing in the Industry, intensified market competition, and contraction in domestic market demand, Shanghai Medicilon Inc. is expected to continue expanding its losses to 0.331 billion yuan in 2024; ② By region, the domestic market is heavily impacted by the reduction in R&D investment from local pharmaceutical companies and price wars, becoming the main drag on performance; the Overseas market, although maintaining growth, has seen increased costs due to new experimental facility investments, squeezing profit margins.

cls.cnApr 21 11:11 ET

The Equity Transfer of the symbol has not been delivered, and Bidu Medicine terminates the significant Assets reorganization.

① Regarding the termination of the merger and acquisition, the company stated that the failure to complete the delivery of 100% equity of the target company as expected has resulted in the inability to achieve the purpose of this Trade. Liu Weidong stated that the termination of this acquisition will not affect the company's established Global Strategy layout; ② Bid Pharma has completed the construction of the R&D center and the upgrade of storage facilities in the USA market last year.

cls.cnApr 15 08:33 ET

This week adds 14 more! WUXI APPTEC and several other stocks disclosed repurchases and increased loan quotas exceeding 0.2 billion yuan, a list of related A-shares overview.

According to incomplete Statistics from the Financial Association, as of the time of this report, over 14 companies announced that associated parties had procured shareholding repurchase loans exceeding 0.2 billion yuan; HAIER SMARTHOME and Rongsheng Petro Chemical received the highest specialized loan quotas for repurchase shareholding, both at 1.8 billion yuan.

cls.cnApr 13 05:10 ET

Strong policies to maintain stability inject confidence, the Agriculture chain and CSI Consumer 360 index are expected to progress together.

Track the entire lifecycle of the main Sector.

cls.cnApr 8 21:28 ET

The U.S. tariff policy will not affect overseas clients signing contracts. Joinn Laboratories: Focus on the expansion of offshore outsourcing Business | Directly covering the Earnings Conference.

In the Earnings Conference, Joinn Laboratories stated that due to reasons such as the services provided by the company not falling within the scope of tariff implications, the USA's tariff policy will not affect the signing of overseas customer Orders. The company's CFO answered questions regarding the reasons for the decline in overseas Business revenue and gross margin in 2024, as well as the company's Operation plans for 2025.

cls.cnApr 7 09:21 ET